Navigation Links
Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
Date:5/19/2008

San Diego, California, May 19, 2008 NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the presentation of Phase 3 data at the annual Digestive Disease Week (DDW) Congress on GATTEX (teduglutide), a novel investigational compound that may reduce dependence upon parenteral nutrition (PN) in patients with intestinal failure associated with short bowel syndrome (SBS).

The Phase 3 study evaluated two doses of GATTEX versus placebo. Results indicate that GATTEX was generally well-tolerated and effective in reducing the PN requirements of SBS patients, with the lower dose findings showing statistical significance versus placebo. The company is finalizing a protocol for a Phase 3 confirmatory study, which it expects will begin in the third quarter of 2008. Stephen OKeefe, M.D., professor of medicine, University of Pittsburgh, presented the Phase 3 results today at an American Gastroenterological Association (AGA) Institute clinical science plenary session.

Data from this study show that GATTEX has the potential to reduce or eliminate the need for parenteral nutrition, thereby reducing the complications associated with PN therapy and improving quality of life for patients with intestinal failure due to surgical resection (SBS), said Dr. OKeefe. These latest findings provide further support for the development of GATTEX as a potential first-in-class compound to reduce the dependency of SBS patients on IV fluids and nutrition without adverse side effects.

The pivotal Phase 3 study evaluated 83 SBS patients who are dependent on PN. After a PN stabilization and optimization period, patients were randomized to receive low-dose of GATTEX (0.05 mg/kg/day), high-dose GATTEX (0.10 mg/kg/day) or placebo for 24 weeks. A clinically significant PN response was defined as a weekly reduction of PN requirements of more than 20% at dosing week 20 and maintained through dosing week 24.

Key findings were as follows:


  • '/>"/>

Contact: Stephen Bingham
609-514-5117
JFK Communcations
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
2. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
3. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
4. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
5. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
6. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
7. Wal-Mart Launches Phase Three of $4 Prescription Program
8. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
9. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
10. Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
11. QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... 10 million older Americans suffer from depression, often brought ... new research a project that followed the lives ... found that Internet use among the elderly can ... percent. , "That,s a very strong effect," said Shelia ... studies and media who led the project. "And it ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... a colored ribbon representing a disease. A pink ribbon is ... does one think of with lung cancer?, Although white has ... the disease, black may be the only one they think ... patients, primarily smokers between the ages of 51 to 79 ... felt by these patients, the emotional toll it can have ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2
... TORONTO, Ont., Aug. 29, 2011The Echocardiography and Vascular Laboratory ... its commitment to quality patient care and testing for ... accredited by the Intersocietal Commission for the Accreditation of ... of approval" that patients can rely on as an ...
... of chocolate consumption might be associated with a one ... finds a study published on bmj.com today. ... agree on a potential beneficial link between chocolate consumption ... studies are needed to test whether chocolate actually causes ...
... (HealthDay News) -- Although it may sound sweet and ... similar to arguing or slinging insults, Canadian scientists have ... University in Kingston, Ontario, also revealed that differences among ... play a role in how aggressive their shouting matches ...
... News) -- As another school year begins, parents are ... other supplies can lead to back injury. "Parents ... They often carry much more than they should with ... Dr. Joshua Hyman, director of orthopedic surgery at New ...
... 26 (HealthDay News) -- Scientists report an advance in the ... women of childbearing age. Uterine fibroids, which can cause ... of women by the age 45. Fibroids are also a ... hysterectomy. Despite their importance, little has been known about ...
... Reporter , FRIDAY, Aug. 26 (HealthDay News) -- Three ... form of complementary or alternative medicine or practice to ... more, doctors, nurses and their assistants, health technicians, and ... the general public to use any number of wide-ranging ...
Cached Medicine News:Health News:It's official -- chocolate linked to heart health 2Health News:Sweet Sparrow Songs May Actually Be Shouting Matches 2Health News:Many Health-Care Workers Have Turned to Alternative Medicine 2Health News:Many Health-Care Workers Have Turned to Alternative Medicine 3
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: